Tysabri Safety Study To Commence Following Lift Of Clinical Hold
Executive Summary
Biogen Idec/Elan's monotherapy safety extension study of its multiple sclerosis therapy Tysabri will help shape FDA's risk management demands for the biologic, assuming it is re-approved
You may also be interested in...
Rituxan Launch For Arthritis, Tysabri Return Expected In Mid-’06, Biogen Says
Biogen Idec could launch Rituxan (rituximab) for rheumatoid arthritis and relaunch Tysabri (natalizumab) for multiple sclerosis by mid-2006, CFO Peter Kellogg said during an Oct. 26 earnings call
Tysabri Withdrawn Pending Analysis Of Safety Signal In Long-Term Trial
Biogen Idec and Elan are convening a panel of experts on progressive multifocal leukoencephalopathy as the first step towards reintroducing the multiple sclerosis therapy Tysabri (natalizumab)
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011